GLP1S

Semaglutide GLP-1 Receptor Agonist Analogue | Research Use Only

Semaglutide is a synthetic analogue of human glucagon-like peptide-1 (GLP-1), engineered with structural modifications to extend circulating half-life. Key modifications include an amino acid substitution at position 8 (Aib for Ala) to confer resistance to DPP-4 degradation, and conjugation of a C18 fatty diacid chain via a hydrophilic linker at lysine 26, enabling reversible albumin binding and prolonged receptor engagement in research models.

In preclinical research, semaglutide has been utilized extensively in studies examining GLP-1 receptor signaling pathways, pancreatic beta cell biology, insulin secretion mechanisms, and central nervous system GLP-1 receptor distribution. It is widely employed in metabolic research models and cardiovascular biology investigations, and serves as a reference compound in studies evaluating GLP-1 receptor agonist pharmacodynamics.

Research Specifications:

• Type: Fatty acid-conjugated GLP-1 receptor agonist analogue
• Target: GLP-1 receptor (GLP1R)
• CAS Number: 910463-68-2
• Molecular Weight: ~4113.6 g/mol
• Purity: ≥98% (HPLC verified)
• Form: Lyophilized powder
• Storage: -20°C, protected from light and moisture

For Research Use Only. This product is not intended for human or veterinary use, diagnosis, or treatment. Not evaluated by the FDA. For qualified research applications only.